Silexion Therapeutics Corp (SLXN) furnishes February 2026 investor roadshow deck

Rhea-AI Filing Summary

Silexion Therapeutics Corp furnished an investor presentation in connection with a non-deal roadshow. The company prepared a corporate presentation dated February 2026 for use in meetings with investors, and attached it as Exhibit 99.1. This material is provided under Regulation FD as a furnished, not filed, communication under securities laws.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000202241600-0000000972NASDAQNASDAQ00020224162026-02-032026-02-030002022416slxn:OrdinarySharesParValue00135PerShareMember2026-02-032026-02-030002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf155250PerShareMember2026-02-032026-02-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 3, 2026

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands		001-42253		N/A
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

12 Abba Hillel Road Ramat-Gan, Israel		5250606
(Address of principal executive offices)		(Zip Code)

+972-3-756-4999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.0135 per share		SLXN		The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share		SLXNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On February 3, 2026, Silexion Therapeutics Corp prepared a corporate presentation for use in meetings with investors as part of a non-deal roadshow. A copy of the presentation is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Form 8-K, including the presentation furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the presentation, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1		Corporate Presentation dated February 2026
104		Cover Page Interactive Data File (formatted in Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILEXION THERAPEUTICS CORP
Date: February 3, 2026	/s/ Ilan Hadar
	Name:	Ilan Hadar
	Title:	Chief Executive Officer

FAQ

What did Silexion Therapeutics Corp (SLXN) disclose in this 8-K?

Silexion Therapeutics Corp furnished a corporate presentation as part of a non-deal roadshow. The presentation, dated February 2026, is included as Exhibit 99.1 and is intended for use in meetings with investors under Regulation FD disclosure rules.

What is the purpose of Silexion Therapeutics Corp’s February 2026 corporate presentation?

The presentation was prepared for use in investor meetings during a non-deal roadshow. It serves as an information tool for existing and potential investors and is furnished under Regulation FD, meaning it is not treated as filed for certain liability purposes.

How is the Silexion (SLXN) investor presentation treated under U.S. securities laws?

The information in the corporate presentation is furnished, not filed, under Section 18 of the Exchange Act. It is also not incorporated by reference into Silexion’s Securities Act filings, limiting how it is used for liability and disclosure purposes.

Which exhibit contains the Silexion Therapeutics Corp February 2026 presentation?

Exhibit 99.1 contains the corporate presentation dated February 2026. The filing also includes Exhibit 104, the cover page interactive data file formatted in Inline XBRL, accompanying the 8-K submitted by Silexion Therapeutics Corp.

What securities of Silexion Therapeutics Corp are listed on Nasdaq?

Silexion’s ordinary shares with a par value of $0.0135 per share trade under symbol SLXN. Warrants exercisable for ordinary shares at an exercise price of $1,552.50 per share trade under symbol SLXNW, both on The Nasdaq Stock Market LLC.

Who signed the Silexion Therapeutics Corp 8-K for the investor presentation?

The 8-K was signed on behalf of Silexion Therapeutics Corp by Ilan Hadar. He is identified in the filing as the company’s Chief Executive Officer and executed the report pursuant to Exchange Act requirements.